APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive: On the other hand, in the presence of CML, a co-injection of either apoA-I (8.5 μg, final 1 μM) or CIGB-258 (0.9 μg, final 1 μM) resulted in higher swimming ability: ~10–13% and ~45–47% at 30 min and 60 min post-injection, respectively.